

LY2562175

Catalog No: tcsc0033341



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg



Specifications

CAS No:

1103500-20-4

Formula:

$C_{28}H_{27}Cl_2N_3O_4$

Pathway:

Metabolic Enzyme/Protease

Target:

FXR

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Storage Instruction:

Dry, Keep in dark ; at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years); Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping.

Observed Molecular Weight:

540.44


Product Description

LY2562175 is a potent and selective **FXR** agonist with an **EC₅₀** of 193 nM.

IC50 & Target: EC50: 193 nM (FXR)

In Vitro: LY2562175 promotes transcriptional activation of human FXR in a cell-based co-transfection assay with an EC₅₀ of 193 nM. LY2562175 promotes recruitment of a peptide from the nuclear receptor interaction domain of the coactivator SRC-1 with a relative EC₅₀ of 121 nM and 93.5% efficacy as compare to GW4064^[1].

In Vivo: LY2562175 causes a dose-dependent decrease in serum cholesterol and serum triglycerides. At a dose of 10 mg/kg, the decrease in cholesterol with LY2562175 is 80% below vehicle-treated animals, and the decrease in serum triglycerides is 76% from control group. The ED₅₀ for serum cholesterol is determined to be 2 and 3.4 mg/kg for serum triglycerides. Treatment of female ZDF rats with LY2562175 results in a dose dependent lowering of plasma triglycerides in the fasted and nonfasted states. When administered as a fixed dose combination with rosiglitazone, LY2562175 further lowers fasted and nonfasted plasma triglycerides. FPLC fractionation of the lipoproteins reveals that LY2562175 treatment results in a reduction in vLDL-C and a dramatic increase in HDL-c in this animal model^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!